Mouse model of oropharyngeal candidiasis
نویسندگان
چکیده
منابع مشابه
New model of oropharyngeal candidiasis in mice.
We established a straightforward murine model of oropharyngeal candidiasis. Mice were immunosuppressed with cortisone acetate, anesthetized, and then inoculated by placing cotton wool balls saturated with Candida albicans sublingually for 2 h. A prolonged, reproducible infection was induced. This model may be useful for antifungal screening or pathogenesis studies.
متن کاملOropharyngeal candidiasis: a new treatment option.
In this issue of Clinical Infectious Diseases, Vazquez et al. [1] demonstrate in a well-conceived and well-conducted multicenter trial that posaconazole is equivalent in efficacy to fluconazole in the treatment of oropharyngeal candidiasis in HIV-infected patients. Patients given posaconazole also experienced fewer clinical relapses of oro-pharyngeal candidiasis than did patients given fluconaz...
متن کاملRethinking T cell immunity in oropharyngeal candidiasis
The disproportionate increase in oropharyngeal candidiasis (OPC) compared with systemic and vaginal candidiasis in female patients with AIDS has been a paradox for almost three decades. New data now show that severe OPC develops in Th17-deficient mice, but not Th1-deficient mice, implicating Th17-induced effector molecules in resistance to oral disease. These findings clarify and extend our cur...
متن کاملOropharyngeal candidiasis in children with lymphohematopoietic malignancies in Mashhad, Iran
Background and Purpose: Over the past years, the role of fungi as a cause of nosocomial infections in hospitalized patients has been accentuated. Candida species constitute an important group of fungi causing diseases in immunocompromised patients. Oropharyngeal candidiasis continues to be a prevalent infection in immunodeficient patients. In this study, we aimed to determine the incidence of o...
متن کاملRole of posaconazole in the treatment of oropharyngeal candidiasis
Posaconazole is the newest azole antifungal approved by the US Food and Drug Administration, and possesses a broad spectrum of activity against numerous yeasts and filamentous fungi. It is available as an oral suspension and is generally well tolerated by patients, but gastrointestinal absorption is sometimes inadequate and remains a clinical concern in treating deep-seated infections. It is us...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Protocols
سال: 2012
ISSN: 1754-2189,1750-2799
DOI: 10.1038/nprot.2012.011